Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025
The Regulatory Advantages of Energetic Therapies Unlike compounded GLP-1 medications facing strict FDA regulations, energetic therapies remain fully compliant with FDA guidelines
Additionally, tirzepatide appeared to yield similar improvements in metabolic parameters such as blood glucose, blood pressure, and lipid profiles among MC4R variant carriers and non-carriers, suggesting its efficacy in MC4R -deficient obesity may be comparable
For example, in a March 5 warning letter, the FDA accused drugmaker Novo Nordisk, the maker of Wegovy and Ozempic, of failing to report some adverse events to the federal government, including suicidal ideation and death
US$ 25.22
US$ 26.63
US$ 24.66
US$ 23.83
